We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
101
DELISTED
Adamas Pharmaceuticals
ADMS
$2.12M 0.09%
+125,504
New +$1.94M
MCK icon
102
McKesson
MCK
$101B
$2.11M 0.09%
15,000
– –
NBRV
103
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.08M 0.09%
+1,400
New +$1.86M
FOLD
104
DELISTED
Amicus Therapeutics
FOLD
$2.08M 0.09%
418,730
+160,730
+62% +$1.11M
HR
105
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.06M 0.09%
+68,000
New +$2.07M
FWP
106
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.05M 0.09%
19,507
– –
HALO icon
107
Halozyme
HALO
$9.88B
$1.98M 0.08%
200,000
– –
ACHN
108
DELISTED
Achillion Pharmaceuticals
ACHN
$1.83M 0.08%
+443,851
New +$2.36M
MDRX
109
DELISTED
Veradigm Inc. Common Stock
MDRX
$1.77M 0.08%
173,600
– –
IPXL
110
DELISTED
Impax Laboratories, Inc.
IPXL
$1.65M 0.07%
124,335
– –
DPLO
111
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$1.64M 0.07%
130,223
+43,060
+49% +$802K
WELL icon
112
Welltower
WELL
$170B
$1.43M 0.06%
+21,400
New +$1.42M
CMRX
113
DELISTED
Chimerix, Inc.
CMRX
$1.42M 0.06%
308,892
– –
XLRN
114
DELISTED
Acceleron Pharma
XLRN
$1.39M 0.06%
+54,450
New +$1.73M
CDTX
115
DELISTED
Cidara Therapeutics
CDTX
$1.38M 0.06%
6,624
– –
DVAX
116
DELISTED
Dynavax Technologies
DVAX
$1.36M 0.06%
345,050
– –
DOC icon
117
Healthpeak Properties
DOC
$15.2B
$1.35M 0.06%
+45,500
New +$1.39M
QURE icon
118
uniQure
QURE
$2.93B
$1.35M 0.06%
241,021
– –
HR icon
119
Healthcare Realty
HR
$7.46B
$1.34M 0.06%
+46,000
New +$1.35M
ESPR
120
DELISTED
Esperion Therapeutics
ESPR
$1.29M 0.05%
102,800
– –
ONCE
121
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.21M 0.05%
+24,300
New +$1.3M
GNMK
122
DELISTED
GenMark Diagnostics, Inc
GNMK
$1.14M 0.05%
93,349
– –
CYH icon
123
Community Health Systems
CYH
$391M
$1.14M 0.05%
203,935
-100,537
-33% -$698K
TXMD icon
124
TherapeuticsMD
TXMD
$23.5M
$1.08M 0.05%
3,742
-2,398
-39% -$743K
JUNO
125
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.07M 0.05%
56,900
-125,100
-69% -$3.06M
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.